LAS VEGAS , Nov. 5, 2024 /PRNewswire/ -- The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announces the results for the final two rounds of Late-Breaking Clinical Trials presented at the VIVA24 conference, at Wynn Las Vegas. VIVA (Vascular InterVentional Advances) is an annual vascular education symposium that brings together a global, multispecialty faculty to present a variety of lectures and live case presentations from clinical centers around the world.
The audience is composed of interventional cardiologists, interventional radiologists, vascular surgeons, and endovascular medicine specialists. Below are highlights of today's 8 late-breaking clinical trial presentations. Two-Year Outcomes From the PROMISE II Trial of Transcatheter Arterialization of the Deep Veins Presented by: Daniel Clair , MD Up to 20% of patients with chronic limb-threatening ischemia (CLTI) are not eligible for conventional surgical or endovascular revascularization techniques and have a resultant amputation rate of 50% within 6 months.
An alternative option for these no-option patients is transcatheter arterialization of the deep veins (TADV) with the purpose-built LimFlow System (Inari Medical), the only FDA-approved option. The LimFlow System consists of an integrated system for arteriovenous crossing, atraumatic vein preparation, and flow diversion. This work reports the 2-year outcomes from .
